Skip to main content

Table 1 Baseline characteristics of patients with pancreatic cancer

From: Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer

Variable

All patients (n = 61)

Median age

64 (41–81)

Sex

 Male

35 (57%)

 Female

26 (43%)

Median tumor size (mm)

37 (11–100)

Median CA 19-9 levels

385.5 (5–102041)

CA 19-9

 < 37U/mL

13 (21%)

 ≥ 37U/mL

47 (77%)

 Missing data

1 (2%)

Tumor location

 Pancreas head

34 (56%)

 Pancreas body

4 (7%)

 Pancreas tail

13 (21%)

 Multiple

10 (16%)

T-stage

 T2

11 (18%)

 T3

15 (25%)

 T4

25 (41%)

 TX

2 (3%)

 Missing data

8 (13%)

Clinical stage

 Stage III

6 (10%)

 Stage IV

55 (90%)

Metastatic location

 Liver

25 (41%)

 Lung

4 (7%)

 Multiple

16 (26%)

 Other

6 (10%)

 Missing data

10 (16%)

N-stage

 N0

14 (23%)

 N1

25 (41%)

 NX

21 (34%)

 Missing data

1 (2%)

ECOG status

 0

13 (21%)

 1

34 (56%)

 2

10 (16%)

 Missing data

4 (7%)

First-line treatment

 Gemcitabine

6 (10%)

 FOLFIRINOX

30 (49%)

 Nab-Paclitaxel +

25 (41%)

 Gemcitabine

Second-line treatment

 Yes

17 (28%)

 No

44 (72%)

Prior anti-cancer surgery

 Yes

9 (15%)

 No

51 (84%)

 Missing data

1 (2%)